Sodium–glucose co‐transporter‐2 inhibitors and arterial stiffness: Class effect or drug effect?

Documenti analoghi

• Time to assess the effects of sodium–glucose co‐transporter‐2 inhibitors on the ‘forgotten' right ventricle?
  di: Patoulias, Dimitrios, et al.
  Pubblicazione: (2019)
• Sodium–Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions
  di: Patoulias, Dimitrios, et al.
  Pubblicazione: (2020)
• Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodium‐glucose co‐transporter‐2 inhibitors
  di: Patoulias, Dimitrios, et al.
  Pubblicazione: (2020)
• Surrogate cardiovascular outcomes with sodium-glucose co-transporter-2 inhibitors in women: An updated meta-analysis
  di: Patoulias, Dimitrios, et al.
  Pubblicazione: (2021)
• Meta‐analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium‐glucose co‐transporter‐2 inhibitors: Implications for the COVID‐19 pandemic
  di: Patoulias, Dimitrios, et al.
  Pubblicazione: (2021)